[go: up one dir, main page]

MX2011012680A - Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune. - Google Patents

Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune.

Info

Publication number
MX2011012680A
MX2011012680A MX2011012680A MX2011012680A MX2011012680A MX 2011012680 A MX2011012680 A MX 2011012680A MX 2011012680 A MX2011012680 A MX 2011012680A MX 2011012680 A MX2011012680 A MX 2011012680A MX 2011012680 A MX2011012680 A MX 2011012680A
Authority
MX
Mexico
Prior art keywords
cells
autoimmune
isolation
treatment
peptoid ligands
Prior art date
Application number
MX2011012680A
Other languages
English (en)
Inventor
Anne R Gocke
D Gomika Udugamasooriya
Thomas Kodadek
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2011012680A publication Critical patent/MX2011012680A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)

Abstract

La presente invención proporciona la identificación de poblaciones de célula T autorreactivas de individuos que tienen enfermedades autoinmune, tal como esclerosis múltiple y EAE. Los peptoides reconocidos por las células T autorreactivas se pueden utilizar para identificar varios tipos de enfermedad autoinmune, y también se pueden utilizar para dirigir terapias contra dichas poblaciones.
MX2011012680A 2009-05-29 2010-05-28 Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune. MX2011012680A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18236809P 2009-05-29 2009-05-29
US26060809P 2009-11-12 2009-11-12
PCT/US2010/036537 WO2010138797A1 (en) 2009-05-29 2010-05-28 Peptoid ligands for isolation and treatment of autoimmune t-cells

Publications (1)

Publication Number Publication Date
MX2011012680A true MX2011012680A (es) 2012-03-06

Family

ID=42335126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012680A MX2011012680A (es) 2009-05-29 2010-05-28 Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune.

Country Status (15)

Country Link
US (2) US20100303835A1 (es)
EP (1) EP2435827A1 (es)
JP (2) JP5991916B2 (es)
KR (1) KR20120034683A (es)
CN (1) CN102449481B (es)
AU (1) AU2010253797B2 (es)
BR (1) BRPI1014995A2 (es)
CA (1) CA2763685A1 (es)
CL (1) CL2011002959A1 (es)
CO (1) CO6440595A2 (es)
IL (1) IL216658A (es)
MX (1) MX2011012680A (es)
RU (1) RU2563822C2 (es)
TW (1) TWI606238B (es)
WO (1) WO2010138797A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2764153C (en) 2009-06-02 2021-07-27 The Board Of Regents Of The University Of Texas System Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
EP2663321A4 (en) * 2011-01-10 2014-12-03 Opko Pharmaceuticals Llc ANTIGENIC SUBSTITUTES IN AUTOIMMUNE DISEASE
EP2688911B1 (en) 2011-03-24 2017-08-02 OPKO Pharmaceuticals, LLC Biomarker discovery in complex biological fluid using bead or particle based libraries
WO2014179714A1 (en) * 2013-05-03 2014-11-06 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
EP3313866B1 (en) * 2015-06-29 2024-11-20 University Of Louisville Research Foundation, Inc. Compositions and methods for treating cancer and promoting wound healing
AU2016338410B2 (en) 2015-10-14 2021-07-15 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
EP3426672B1 (en) * 2016-03-09 2021-09-01 Mike-Ann, LLC Peptoid affinity ligands
US10458995B2 (en) 2016-03-25 2019-10-29 Muralidhar Reddy Moola Combinatorial synthesis and biomarker development
CN108588020B (zh) * 2018-03-30 2021-09-14 中国科学院苏州纳米技术与纳米仿生研究所 一种含有硒元素的近红外ii区量子点的新应用
CN110045105B (zh) * 2018-11-09 2022-04-26 广州市妇女儿童医疗中心 柯萨奇A16病毒IgA抗体量子点免疫荧光层析试纸条及试剂盒
US12479886B2 (en) * 2019-07-03 2025-11-25 University Of Houston System Inhibitors of IL-15 and their use in treating autoimmune/inflammatory disorders
US12343375B2 (en) 2021-02-09 2025-07-01 University Of Louisville Research Foundation, Inc. Spray dried formulation of a cholera toxin B subunit variant
CN113024643B (zh) * 2021-04-30 2022-05-13 武汉大学 一种人工拟肽及其制备方法和应用
CN119290543B (zh) * 2024-12-13 2025-03-21 天津医科大学总医院空港医院 一种同时检测淋巴组织中il-6、il-21与t细胞cd4表面分子的试剂盒及方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011771A (en) * 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4789628A (en) * 1986-06-16 1988-12-06 Vxr, Inc. Devices for carrying out ligand/anti-ligand assays, methods of using such devices and diagnostic reagents and kits incorporating such devices
US5149626A (en) * 1987-05-14 1992-09-22 Mclean Hospital Corporation Multiple antigen immunoassay
CA2115333A1 (en) * 1993-02-16 1994-08-17 Shigeo Hozumi Polyfunctional vinyl ether compounds and photoresist resin composition containing the same
US5705614A (en) * 1993-04-09 1998-01-06 Chiron Corporation Methods of producing antigen forks
DE69432791T2 (de) * 1993-05-28 2004-06-03 Baylor College Of Medicine, Houston Verfahren und massenspektrometer zur desorption und ionisierung von analyten
ZA95605B (en) * 1994-04-28 1995-12-20 Qualcomm Inc Method and apparatus for automatic gain control and dc offset cancellation in quadrature receiver
AUPO591797A0 (en) * 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP2055712A1 (en) * 1995-06-07 2009-05-06 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US20020022227A1 (en) * 1996-10-17 2002-02-21 Short Jay M. Morphatides: novel shape and structure libraries
US20020006620A1 (en) * 1996-10-17 2002-01-17 Invitrogen Corporation Morphatides: novel shape and structure libraries
WO1998027209A1 (en) * 1996-12-18 1998-06-25 Emory University Polycationic oligomers
WO1998046796A1 (en) * 1997-04-11 1998-10-22 The Regents Of The University Of California A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6406632B1 (en) * 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
AU4829099A (en) * 1998-06-22 2000-01-10 Regents Of The University Of California, The Triggered optical biosensor
US6780582B1 (en) * 1998-07-14 2004-08-24 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
US6406921B1 (en) * 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
US6197599B1 (en) * 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
US6306643B1 (en) * 1998-08-24 2001-10-23 Affymetrix, Inc. Methods of using an array of pooled probes in genetic analysis
US6465183B2 (en) * 1999-07-01 2002-10-15 Agilent Technologies, Inc. Multidentate arrays
GB9919452D0 (en) * 1999-08-17 1999-10-20 Osteometer Biotech As Specific autoimmune reactions against isomerised/optically inverted epitopes:application for diagnosis of autoimmune diseases
CA2383945A1 (en) * 1999-10-08 2001-04-19 Li Shen Compositions and methods for detecting protein modification and enzymatic activity
JP2004501869A (ja) * 2000-03-22 2004-01-22 ソルリンク・インコーポレイテッド ヒドラジンベース及びカルボニルベースの二官能性架橋剤
AU5951201A (en) * 2000-05-04 2001-11-12 Univ Yale High density protein arrays for screening of protein activity
EP1287363A2 (en) * 2000-05-25 2003-03-05 Sunol Molecular Corporation Modulation of t-cell receptor interactions
WO2001092577A1 (en) * 2000-05-25 2001-12-06 Evorx Extracellular drug-oligonucleotides chimeric molecules
US7153682B2 (en) * 2000-06-05 2006-12-26 Chiron Corporation Microarrays on mirrored substrates for performing proteomic analyses
ATE360207T1 (de) * 2000-06-05 2007-05-15 Novartis Vaccines & Diagnostic Mikroarrays für durchführen von proteomanalyse
WO2002014860A1 (en) * 2000-08-15 2002-02-21 Discerna Limited Functional protein arrays
GB0022978D0 (en) * 2000-09-19 2000-11-01 Oxford Glycosciences Uk Ltd Detection of peptides
EP1337667A2 (en) * 2000-11-16 2003-08-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
EP1343914A2 (en) * 2000-12-11 2003-09-17 HK Pharmaceuticals, Inc. Multiplexed protein expression and activity assay
CA2434139C (en) * 2001-01-23 2014-05-27 President And Fellows Of Harvard College Nucleic-acid programmable protein arrays
US20020137106A1 (en) * 2001-03-09 2002-09-26 Ciphergen Biosystems, Inc. Detection of biological pathway components
WO2002084249A2 (en) * 2001-04-10 2002-10-24 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles
WO2002084252A2 (en) * 2001-04-17 2002-10-24 Xenoport, Inc. Epitope-captured antibody display
JP2004536290A (ja) * 2001-04-19 2004-12-02 ゲゼルシャフト　フュア　バイオテクノロギッシェ　フォーシュンク　エム　ベー　ハー（ゲー　ベー　エフ） 安定した、再生可能な抗体アレイの作製方法
US6989276B2 (en) * 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
NO20013192L (no) * 2001-06-25 2002-12-27 Medinnova As Metode for monitering av T-celler
WO2003019192A1 (en) * 2001-08-27 2003-03-06 The Trustees Of Boston University Apparatus, composition and method for proteome profiling
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
US7884052B2 (en) * 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
JP4864425B2 (ja) * 2005-03-18 2012-02-01 株式会社膠原病研究所 全身性エリテマトーデスの発症の判定のためのデータ取得方法およびその利用
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists

Also Published As

Publication number Publication date
JP2016185147A (ja) 2016-10-27
CN102449481A (zh) 2012-05-09
CN102449481B (zh) 2016-05-25
RU2563822C2 (ru) 2015-09-20
IL216658A0 (en) 2012-02-29
IL216658A (en) 2016-11-30
EP2435827A1 (en) 2012-04-04
WO2010138797A1 (en) 2010-12-02
US20130178835A1 (en) 2013-07-11
AU2010253797A1 (en) 2011-10-27
BRPI1014995A2 (pt) 2016-04-26
CA2763685A1 (en) 2010-12-02
TW201109658A (en) 2011-03-16
JP2012527904A (ja) 2012-11-12
CO6440595A2 (es) 2012-05-15
KR20120034683A (ko) 2012-04-12
US20100303835A1 (en) 2010-12-02
CL2011002959A1 (es) 2012-03-23
TWI606238B (zh) 2017-11-21
JP5991916B2 (ja) 2016-09-14
AU2010253797B2 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
MX2011012680A (es) Ligandos peptoides para aislamiento y tratamiento de celulas-t autoinmune.
IN2014MN01642A (es)
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
MX382244B (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales
MX355543B (es) Macrociclos peptidomiméticos.
CR20110470A (es) Proteínas de union a il-17
MX2011012913A (es) Métodos para evaluar el riesgo de cáncer de mama.
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
PH12014502436A1 (en) In vitro method for the diagnosis and surveillance of cancer
WO2013126720A3 (en) Compositions and methods for the assessment of target cancer cell resistance to car engineered t cell killing
MX356254B (es) Aleaciones de magnesio-aluminio diseñadas especialmente y usos medicos de las mismas en un ambiente hemodinamico.
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
IN2014MN01493A (es)
MX2013006188A (es) Agentes de generacion de imagenes pet de apoptosis.
GB201102108D0 (en) Diagnostic method
SG195302A1 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
PH12014502798A1 (en) Nalmefene for reduction of alcohol consumption in specific target populations
PH12015500639A1 (en) Residual disinfection of water
GB0818080D0 (en) Immunogenic peptides
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
WO2015092435A3 (en) Conjugates for treating inflammatory disease and identification of patients likely to benefit from such treatment